Wednesday, November 18, 2026
Sign In
★ ★ ★

The American Minds

Independent Reporting · Est. 2020
BackBusiness

Rosemont Pharmaceuticals to Acquire Aytu BioPharma in Cash Tender Offer

Aytu BioPharma entered a definitive merger agreement with Rosemont Pharmaceuticals, with shareholders receiving Two Dollars and Seventy Cents per share in cash.

Rosemont Pharmaceuticals to Acquire Aytu BioPharma in Cash Tender Offer

Rosemont Pharmaceuticals to Acquire Aytu BioPharma in Cash Tender Offer

Aytu BioPharma announced Monday that it has entered into a definitive merger agreement with Rosemont Pharmaceuticals Holdings, Inc., under which Rosemont will acquire Aytu through a cash tender offer valued at $2.70 per share, followed by a back-end merger to capture any remaining shares.

The transaction, disclosed in Aytu's fiscal 2027 first quarter earnings release on November 16, 2026, represents a strategic consolidation in the specialty pharmaceuticals sector, with Rosemont seeking to expand its portfolio of central nervous system therapies and pediatric-focused medicines.

Aytu BioPharma, a Denver-based pharmaceutical company, has built its business around advancing innovative medicines for complex CNS diseases, including major depressive disorder and attention deficit/hyperactivity disorder. The company's EXXUA product line has shown strong sequential growth, with net revenue reaching $4.9 million in the most recent quarter, up 24.5 percent from the prior quarter, and total prescriptions surging 32.5 percent to 4,400.

However, Aytu's ADHD portfolio has faced headwinds from generic competition and reduced promotional emphasis, with net revenue falling to $7.7 million in the first quarter of fiscal 2027 compared to $13.2 million in the prior-year period. The shift in the competitive landscape likely influenced the board's decision to explore strategic alternatives, culminating in the Rosemont merger agreement.

Under the terms of the deal, Aytu stockholders will receive $2.70 in cash for each share they hold, providing immediate liquidity and a premium to recent trading levels. The transaction structure—a tender offer followed by a merger—is designed to allow Rosemont to acquire control rapidly while ensuring that all shareholders can participate at the same price.

Rosemont Pharmaceuticals, the acquirer, gains a commercial-stage company with an established sales infrastructure and a growing CNS franchise anchored by EXXUA. The acquisition aligns with broader industry trends, where larger pharmaceutical companies or private equity-backed platforms seek to consolidate specialty drug portfolios and achieve operating synergies.

Notably, Aytu announced that it will not hold an earnings conference call to discuss its first quarter results, citing the pending merger. This departure from standard practice underscores the company's focus on completing the transaction and transitioning to private ownership under Rosemont's control.

The merger is expected to close following the satisfaction of customary conditions, including the tender of a majority of Aytu's outstanding shares and regulatory approvals. Once complete, Aytu will cease to be a publicly traded entity, marking the end of its independent chapter and the beginning of its integration into Rosemont's pharmaceutical platform.